B4GALNT1 and renal carcinoma: Other research has shown that transferrin (TF) and beta-1,4-N-acetyl-galactosaminyltransferase 1 (B4GALNT1) are highly expressed in patients with ccRCC, and B4GALNT1 may affect the occurrence and progression of renal cancer through the Hippo signaling pathway (Yang et al., 2019a).